162 related articles for article (PubMed ID: 37392405)
1. Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health study.
Cronjé HT; Liu X; Odden MC; Moseholm KF; Seshadri S; Satizabal CL; Lopez OL; Bis JC; Djoussé L; Fohner AE; Psaty BM; Tracy RP; Longstreth WT; Jensen MK; Mukamal KJ
Alzheimers Dement; 2023 Dec; 19(12):5672-5680. PubMed ID: 37392405
[TBL] [Abstract][Full Text] [Related]
2. Serum total tau, neurofilament light, and glial fibrillary acidic protein are associated with mortality in a population study.
Halloway S; Evans DA; Desai P; Dhana K; Beck T; Rajan KB
J Am Geriatr Soc; 2024 Jan; 72(1):149-159. PubMed ID: 37818793
[TBL] [Abstract][Full Text] [Related]
3. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study.
Verberk IMW; Laarhuis MB; van den Bosch KA; Ebenau JL; van Leeuwenstijn M; Prins ND; Scheltens P; Teunissen CE; van der Flier WM
Lancet Healthy Longev; 2021 Feb; 2(2):e87-e95. PubMed ID: 36098162
[TBL] [Abstract][Full Text] [Related]
4. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
5. Associations of plasma NfL, GFAP, and t-tau with cerebral small vessel disease and incident dementia: longitudinal data of the AGES-Reykjavik Study.
van Gennip ACE; Satizabal CL; Tracy RP; Sigurdsson S; Gudnason V; Launer LJ; van Sloten TT
Geroscience; 2024 Feb; 46(1):505-516. PubMed ID: 37530894
[TBL] [Abstract][Full Text] [Related]
6. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
7. Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank.
Wang X; Shi Z; Qiu Y; Sun D; Zhou H
BMC Med; 2024 May; 22(1):192. PubMed ID: 38735950
[TBL] [Abstract][Full Text] [Related]
8. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression.
Hviid CVB; Benros ME; Krogh J; Nordentoft M; Christensen SH
J Affect Disord; 2023 Oct; 338():341-348. PubMed ID: 37336248
[TBL] [Abstract][Full Text] [Related]
9. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
10. Serum Tau, Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Ubiquitin Carboxyl-Terminal Hydrolase L1 Are Associated with the Chronic Deterioration of Neurobehavioral Symptoms after Traumatic Brain Injury.
Lange RT; Lippa S; Brickell TA; Gill J; French LM
J Neurotrauma; 2023 Mar; 40(5-6):482-492. PubMed ID: 36170576
[TBL] [Abstract][Full Text] [Related]
11. Association of Serum Neurofilament Light Chain Concentration and MRI Findings in Older Adults: The Cardiovascular Health Study.
Fohner AE; Bartz TM; Tracy RP; Adams HHH; Bis JC; Djousse L; Satizabal CL; Lopez OL; Seshadri S; Mukamal KJ; Kuller LH; Psaty BM; Longstreth WT
Neurology; 2022 Mar; 98(9):e903-e911. PubMed ID: 34921102
[TBL] [Abstract][Full Text] [Related]
12. Combination of plasma amyloid beta
Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
[TBL] [Abstract][Full Text] [Related]
13. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
[TBL] [Abstract][Full Text] [Related]
14. Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment.
Asken BM; VandeVrede L; Rojas JC; Fonseca C; Staffaroni AM; Elahi FM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Boxer AL; Miller BL; Rosen HJ; Kramer JH; Casaletto KB
J Int Neuropsychol Soc; 2022 Jul; 28(6):588-599. PubMed ID: 34158138
[TBL] [Abstract][Full Text] [Related]
15. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM
Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378
[TBL] [Abstract][Full Text] [Related]
16. Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort.
Gonzales MM; Wang CP; Short MI; Parent DM; Kautz T; MacCarthy D; Satizabal CL; González DA; Royall DR; Zare H; O'Bryant S; Maestre GE; Tracy RP; Seshadri S
Alzheimers Dement (Amst); 2022; 14(1):e12298. PubMed ID: 35356487
[No Abstract] [Full Text] [Related]
17. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL.
Chen CH; Cheng YW; Chen YF; Tang SC; Jeng JS
J Neuroinflammation; 2020 Apr; 17(1):124. PubMed ID: 32321529
[TBL] [Abstract][Full Text] [Related]
18. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B
Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932
[TBL] [Abstract][Full Text] [Related]
19. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
Frontera JA; Boutajangout A; Masurkar AV; Betensky RA; Ge Y; Vedvyas A; Debure L; Moreira A; Lewis A; Huang J; Thawani S; Balcer L; Galetta S; Wisniewski T
Alzheimers Dement; 2022 May; 18(5):899-910. PubMed ID: 35023610
[TBL] [Abstract][Full Text] [Related]
20. Blood biomarkers for dementia in Hispanic and non-Hispanic White adults.
Gonzales MM; Short MI; Satizabal CL; O' Bryant S; Tracy RP; Zare H; Seshadri S
Alzheimers Dement (N Y); 2021; 7(1):e12164. PubMed ID: 33860071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
